Scribe Therapeutics, Inc.: AH Bio Fund II, L.P. discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
AH Bio Fund II, L.P. disclosed a stake exceeding 5% in Scribe Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001725721-26-000009). The filing signals the fund's position has crossed the threshold requiring public disclosure under SEC beneficial ownership rules. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G amendments or 13D filings that could indicate whether the stake is passive or activist in nature.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Scribe Therapeutics, Inc., AH Bio Fund II, L.P.